Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Todos Medical Ltd TOMDF

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor... see more

Recent & Breaking News (GREY:TOMDF)

Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient

GlobeNewswire May 6, 2022

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

GlobeNewswire May 2, 2022

Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022

GlobeNewswire April 27, 2022

Todos Medical to Present at the Emerging Growth Conference

GlobeNewswire April 25, 2022

Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics

GlobeNewswire April 21, 2022

Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study

GlobeNewswire April 20, 2022

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group

GlobeNewswire April 19, 2022

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label

GlobeNewswire April 6, 2022

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

GlobeNewswire April 4, 2022

Update: Todos Medical Reports Fourth-Quarter and  Full-Year 2021 Financial Results and Corporate Updates

GlobeNewswire April 1, 2022

Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates

GlobeNewswire April 1, 2022

Todos Medical Reports Case Study of Patient with Long COVID

GlobeNewswire March 31, 2022

Billy Blanks® Endorses Todos Medical's Line of Tollovid® Products

GlobeNewswire March 28, 2022

Todos Medical to Present at the Proactive One2One Virtual Forum

GlobeNewswire March 17, 2022

Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma

GlobeNewswire March 16, 2022

Todos Medical to Present at the Emerging Growth Conference

GlobeNewswire March 15, 2022

Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs

GlobeNewswire March 8, 2022

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir(TM) in the Treatment of Hospitalized COVID-19 Patients

GlobeNewswire January 27, 2022

Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

GlobeNewswire January 24, 2022

Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical's Tollovid®

GlobeNewswire January 19, 2022